Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAgronomics Regulatory News (ANIC)

Share Price Information for Agronomics (ANIC)

Share Price is delayed by 15 minutes
Get Live Data
5.80    0.00 (0.00%)
Bid:
5.60
Ask:
6.00
Spread: 0.40 (7.143%)
Market Cap: £62.84m
ANIC Live PriceLast checked at - London Stock Exchange

Intraday Agronomics Share Chart

Exercise of Warrants

10 Jan 2022 08:12

RNS Number : 9132X
Agronomics Limited
10 January 2022
 

10 January 2022

Agronomics Limited

("Agronomics" or the "Company")

Exercise of Warrants

Agronomics Limited (AIM:ANIC), a leading listed company focused on cellular agriculture, announces that pursuant to the receipt of notice for the exercise of warrants, it is issuing 5,872 new Ordinary Shares with a nominal value of £0.000001 each in the capital of the Company ("Shares") at a subscription price of 30.0p per Share, and 567,012 new Shares at a subscription price of 28.5p per Share. The Company has received gross proceeds of £163,360.

Application has been made for the 572,884 new Shares to be admitted to trading on AIM ("Admission"), with Admission expected to occur on or around 14 January 2022.

The new Shares will rank pari passu with the existing Shares, including the right to receive all dividends and other distributions declared after the date of their issue.

Following Admission of the new Shares, the Company will have 938,590,207 ordinary shares with a nominal value of £0.000001 each in issue with voting rights and admitted to trading on AIM. This figure may then be used by shareholders in the Company as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

For further information please contact:

 

Agronomics

Limited

Beaumont

Cornish Limited

Cenkos

Securities Plc

Peterhouse Capital

Limited

 

TB Cardew

The Company

Nomad

Joint Broker

Joint Broker

Public Relations

Richard Reed

Denham Eke

Roland Cornish

James Biddle

Giles Balleny

Michael Johnson

Lucy Williams

Charles Goodfellow

Ed Orlebar

Joe McGregor

+44 (0) 1624 639396

info@agronomics.im

+44 (0) 207 628 3396

+44 (0) 207 397 8900

+44 (0) 207 469 0936

+44 (0) 20 7930 0777

+44 (0) 7738 724 630

agronomics@tbcardew.com

 

 

About Agronomics

Agronomics is a leading listed alternative proteins company with a focus on cellular agriculture and cultivated meat. The Company has established a portfolio of 16 companies at the Seed to Series B stage in this rapidly advancing sector. It seeks to secure minority stakes in companies owning technologies with defensible intellectual property that offer new ways of producing food and materials with a focus on products historically derived from animals. These technologies are driving a major disruption in agriculture, offering solutions to improve sustainability, as well as addressing human health, animal welfare and environmental damage. This disruption will decouple supply chains from the environment and animals, as well as being fundamental to feeding the world's expanding population. A full list of Agronomics' portfolio companies is available at https://agronomics.im/.

 

About the Cultivated Meat Sector

Funding in the cultivated meat sector is growing rapidly with approximately US$ 170 million invested worldwide between 2016-2019 and over US$ 270 million raised in 2020 alone. Additional financings are anticipated as the capital requirements of these companies grows to build out and scale up manufacturing facilities. Currently it is estimated that there are 60 companies globally within the sector. AT Kearney, a global consultancy, has predicted that Cultivated Meat's market share of meat consumption will be 35% by 2040.

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ('MAR'). Upon the publication of this announcement via a Regulatory Information Service ('RIS'), this inside information is now considered to be in the public domain.

ENDS

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IOEEAPFEFENAEEA
Date   Source Headline
25th Jun 20267:00 amRNS-RPortfolio company Tropic acquires Rahan Meristem
4th Jun 20265:59 pmRNS-RAgronomics portfolio company HydGene Update
4th Jun 20265:58 pmRNS-RAgronomics portfolio company Bond Pet Foods Update
18th May 20267:00 amRNSNet Asset Value calculation as at 31 March 2026
12th May 20267:00 amRNSAgronomics leads US$5m investment in SuperMeat
7th May 20264:04 pmRNSMeatly completes £10.4 million Series A funding
15th Apr 20261:29 pmRNS-RClean Food Group Update
14th Apr 20267:00 amRNS-RTropic’s product receives regulatory approval
1st Apr 202612:50 pmRNS-RAll G secures FDA "no questions" letter
25th Mar 20263:45 pmRNS-RClean Food Group Update
19th Mar 202612:30 pmRNS-RTropic Biosciences Update
12th Mar 20265:31 pmRNSDirector's Dealing
4th Mar 20267:00 amRNSDirector’s Dealing
25th Feb 20265:04 pmRNSDirector’s Dealing
20th Feb 20265:15 pmRNSDirector’s Dealing
19th Feb 20262:10 pmRNSDirector’s Dealing
17th Feb 20267:00 amRNSHalf-year Financial Report
13th Feb 20264:31 pmRNSResult of AGM
9th Feb 20267:00 amRNSNet Asset Value calculation as at 31 December 2025
15th Jan 20267:00 amRNSAgronomics invests A$3m in All G & Issue of Equity
30th Dec 20258:00 amRNSFinal Results and Notice of AGM
30th Dec 20258:00 amRNSFinal Results and Notice of AGM
30th Dec 20257:00 amRNSFurther equity investment in BlueNalu
30th Dec 20257:00 amRNSFurther equity investment in BlueNalu
19th Dec 20259:30 amRNSLiberation Bioindustries Series A1 equity round
19th Dec 20259:30 amRNSDissolution of Meatable
19th Dec 20259:30 amRNSDissolution of Meatable
19th Dec 20259:30 amRNSLiberation Bioindustries Series A1 equity round
21st Nov 20258:00 amRNSAgronomics invests US$ 2 million in SuperMeat
13th Nov 20257:00 amRNSNet Asset Value as at 30 September 2025
10th Nov 20257:00 amRNS-REVERY raise US$ 55 million in fresh capital
21st Oct 20257:00 amRNS-RGeltor, Inc Update
30th Sep 20257:00 amRNS-RClean Food Group Update
23rd Sep 20257:00 amRNS-ROnego Bio Update
12th Sep 20258:00 amRNS-RClean Food Group Update
22nd Aug 20258:19 amRNS-RMeatable acquires Meat Technology platform
24th Jul 20257:00 amRNS-RSolar Foods Update
18th Jul 202511:00 amRNSNet Asset Value calculation as at 30 June 2025
11th Jun 20257:00 amRNS-RAgronomics Q2 2025 Newsletter
28th May 20252:55 pmRNS-RMeatly reduces bioreactor and medium costs
12th May 20257:00 amRNSNet Asset Value calculation as at 31 March 2025
8th May 20257:00 amRNS-RLiberation Labs Announce Manufacturing Partnership
6th May 20257:00 amRNS-RMeatable and TruMeat Forge Alliance
30th Apr 20257:00 amRNS-RBlueNalu Expands Partnership with Nomad Foods
15th Apr 20259:00 amRNS-RLiberation Labs secures strategic partnership
18th Mar 20257:00 amRNSExercise of Shellbay options
14th Mar 20258:15 amRNSUnaudited Interim Results
4th Mar 20258:00 amRNS-RSolar Foods Secures €10 million Grant
7th Feb 20253:33 pmRNSResult of AGM
7th Feb 20257:00 amRNS-RMeatly launches first cultivated meat dog treat

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.